Condition: Pediatric Malignant Solid Tumor and Epithelioid Sarcoma · Sponsor: Ono Pharmaceutical Co., Ltd.
This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.
This description comes directly from the study's public registry record.
North America Clinical Trial Support Desk · +18665877745(Toll-Free) · clinical_trial@ono-pharma.com
International Clinical Trial Support Desk · +17162141777(Standard) · clinical_trial@ono-pharma.com
Always discuss trial participation with your own doctor first.
| Yokohama City University Hospital | Yokohama, Kanagawa, Japan | — |
| Osaka International Cancer Institute | Osaka, Osaka, Japan | — |
| National Cancer Center Hospital | Chuo-ku, Tokyo, Japan | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07734116